How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 2)

Before reading, don't forget to head to Part 1 to learn more about Quris' founder Isaac Bentwich, why Quris was developed, and how the company is using its innovative bio-AI drug development…

Continue Reading How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 2)

How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 1)

Many people laud the accomplishments of clinical trials – and for, in some cases, good reason. Clinical trials have been crucial in identifying and developing therapeutic options for patients to…

Continue Reading How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 1)